Limited Edition Golden Llama is here! Check out how you can get one.
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free!
Offering SPR-BLI Services - Proteins provided for free!
Thank you for choosing ACROBiosystems. Would you rate our product and service?
Thank you for choosing ACROBiosystems. Would you rate our product and service?
Here come GMP Grade Cytokines!Free Sample is available!
Here come GMP Grade Cytokines!Free Sample is available!
製造番号 | 種類 | 製品説明 | 構造 | 純度 | 特徴 |
---|---|---|---|---|---|
GP0-V182E6 | HIV-1 (CN54) | Biotinylated HIV-1 [HIV-1/Clade B/C (CN54)] GP120 Protein, His,Avitag™ | ![]() |
![]() ![]() |
|
GP4-V15223 | HIV-1 (CM244) | HIV-1 [HIV-1/Clade E (CM244)] GP120 Protein, His Tag | ![]() |
![]() ![]() |
|
GP5-V15224 | HIV-1 (16055) | HIV-1 [HIV-1/Clade C (16055)] GP120 Protein, His Tag | ![]() |
![]() ![]() |
|
GP4-V15227 | HIV-1 (CN54) | HIV-1 [HIV-1/Clade B/C (CN54)] GP120 Protein, His Tag (MALS verified) | ![]() |
![]() ![]() |
Immobilized Human CD4, Fc Tag (Cat. No. CD4-H5259) at 5 μg/mL (100 μL/well) can bind HIV-1 [HIV-1/Clade E (CM244)] GP120, His Tag (Cat. No. GP4-V15223) with a linear range of 20-156 ng/mL (QC tested).
The purity of HIV-1 [HIV-1/Clade B/C (CN54)] GP120, His Tag (Cat. No. GP4-V15227) is more than 90% and the molecular weight of this protein is around 90-120 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
COM-701 | COM-701 | Phase 2 Clinical | Compugen Ltd | Ovarian Neoplasms; Head and Neck Neoplasms; Solid tumours; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Lung Neoplasms | Details |
SIM-0348 | SIM-0348 | Phase 1 Clinical | Simcere Pharmaceutical Group Ltd | Solid tumours; Neoplasms | Details |
GSK-4381562 | SRF-813; GSK-4381562 | Phase 1 Clinical | Surface Oncology Inc | Neoplasms | Details |
NM1F | NM1F; TGI-2 | Phase 1 Clinical | Hefei TG ImmunoPharma Co Ltd | Solid tumours; Ovarian Neoplasms; Triple Negative Breast Neoplasms; Colorectal Neoplasms; Melanoma | Details |
SHR-2002 | SHR-2002 | Phase 1 Clinical | Suzhou Suncadia Biopharmaceuticals Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd | Neoplasms | Details |
JS-009 | JS009; TAB009; JS-009 | Phase 1 Clinical | Shanghai Junshi Biosciences Co Ltd | Solid tumours; Neoplasms | Details |
PM-1009 | PM1009 | Phase 1 Clinical | Biotheus Inc | Solid tumours; Neoplasms; Lung Neoplasms | Details |
COM-701 | COM-701 | Phase 2 Clinical | Compugen Ltd | Ovarian Neoplasms; Head and Neck Neoplasms; Solid tumours; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Lung Neoplasms | Details |
SIM-0348 | SIM-0348 | Phase 1 Clinical | Simcere Pharmaceutical Group Ltd | Solid tumours; Neoplasms | Details |
GSK-4381562 | SRF-813; GSK-4381562 | Phase 1 Clinical | Surface Oncology Inc | Neoplasms | Details |
NM1F | NM1F; TGI-2 | Phase 1 Clinical | Hefei TG ImmunoPharma Co Ltd | Solid tumours; Ovarian Neoplasms; Triple Negative Breast Neoplasms; Colorectal Neoplasms; Melanoma | Details |
SHR-2002 | SHR-2002 | Phase 1 Clinical | Suzhou Suncadia Biopharmaceuticals Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd | Neoplasms | Details |
JS-009 | JS009; TAB009; JS-009 | Phase 1 Clinical | Shanghai Junshi Biosciences Co Ltd | Solid tumours; Neoplasms | Details |
PM-1009 | PM1009 | Phase 1 Clinical | Biotheus Inc | Solid tumours; Neoplasms; Lung Neoplasms | Details |
COM-701 | COM-701 | Phase 2 Clinical | Compugen Ltd | Ovarian Neoplasms; Head and Neck Neoplasms; Solid tumours; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Lung Neoplasms | Details |
SIM-0348 | SIM-0348 | Phase 1 Clinical | Simcere Pharmaceutical Group Ltd | Solid tumours; Neoplasms | Details |
GSK-4381562 | SRF-813; GSK-4381562 | Phase 1 Clinical | Surface Oncology Inc | Neoplasms | Details |
NM1F | NM1F; TGI-2 | Phase 1 Clinical | Hefei TG ImmunoPharma Co Ltd | Solid tumours; Ovarian Neoplasms; Triple Negative Breast Neoplasms; Colorectal Neoplasms; Melanoma | Details |
SHR-2002 | SHR-2002 | Phase 1 Clinical | Suzhou Suncadia Biopharmaceuticals Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd | Neoplasms | Details |
JS-009 | JS009; TAB009; JS-009 | Phase 1 Clinical | Shanghai Junshi Biosciences Co Ltd | Solid tumours; Neoplasms | Details |
PM-1009 | PM1009 | Phase 1 Clinical | Biotheus Inc | Solid tumours; Neoplasms; Lung Neoplasms | Details |
COM-701 | COM-701 | Phase 2 Clinical | Compugen Ltd | Ovarian Neoplasms; Head and Neck Neoplasms; Solid tumours; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Lung Neoplasms | Details |
SIM-0348 | SIM-0348 | Phase 1 Clinical | Simcere Pharmaceutical Group Ltd | Solid tumours; Neoplasms | Details |
GSK-4381562 | SRF-813; GSK-4381562 | Phase 1 Clinical | Surface Oncology Inc | Neoplasms | Details |
NM1F | NM1F; TGI-2 | Phase 1 Clinical | Hefei TG ImmunoPharma Co Ltd | Solid tumours; Ovarian Neoplasms; Triple Negative Breast Neoplasms; Colorectal Neoplasms; Melanoma | Details |
SHR-2002 | SHR-2002 | Phase 1 Clinical | Suzhou Suncadia Biopharmaceuticals Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd | Neoplasms | Details |
JS-009 | JS009; TAB009; JS-009 | Phase 1 Clinical | Shanghai Junshi Biosciences Co Ltd | Solid tumours; Neoplasms | Details |
PM-1009 | PM1009 | Phase 1 Clinical | Biotheus Inc | Solid tumours; Neoplasms; Lung Neoplasms | Details |
This web search service is supported by Google Inc.